Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

Objectives: A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release syndrome and were treated with tocilizumab; however, a significant percentage of patients evolved. This study aimed to determine the usefulness of anakinra as a rescue treatment for patients w...

Full description

Bibliographic Details
Main Authors: Cristina de la Calle, Francisco López-Medrano, José Luis Pablos, Jaime Lora-Tamayo, Guillermo Maestro-de la Calle, Marcos Sánchez-Fernández, Mario Fernández-Ruiz, María Asunción Pérez-Jacoiste Asín, José Manuel Caro-Teller, Rocío García-García, Mercedes Catalán, Joaquín Martínez-López, Ángel Sevillano, Julia Origüen, Mar Ripoll, Rafael San Juan, Antonio Lalueza, Borja de Miguel, Octavio Carretero, Fernando Aguilar, Carlos Gómez, Estela Paz-Artal, Héctor Bueno, Carlos Lumbreras, José María Aguado
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
Anakinra
Tocilizumab
Therapy
Immunomodulation
Outcome
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221001272

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221001272

Similar Items